|
|
|
|
|
Desonide: profile and news
SkinMedica(R) Reports Positive Results From Desonate(TM) Phase III ... Feb 21, 2006 SkinMedica Reports Positive Results From Desonate Phase III Trials ... Feb 22, 2006 TODAY ON PHARMALIVE.COM Mar 3, 2006 President leaves PediaMed after sales force sold Feb 27, 2006 TODAY ON PHARMALIVE.COM Mar 2, 2006 Connetics Names Freddie Park Vice President, Intellectual Property ... Feb 6, 2006 Connetics Names Freddie Park Vice President, Intellectual Property ... Feb 6, 2006 Connetics Acquires PediaMed Sales Organization; Enters Pediatric ... Jan 10, 2006 Bayer releases dermatologic solutions 11 Dec 2005 Barrier Therapeutics Announces FDA Acceptance of Its New Drug ... Dec 9, 2005 Connetics Names Srabasti Mukherjee Associate Director, Business ... Nov 10, 2005 Connetics Founder Eugene A. Bauer Steps Down as Director after 11 ... Oct 17, 2005 ALTANA Inc Acquires US Dermatology Business from GlaxoSmithKline ... Sep 30, 2005 Connetics Launches AcneMedicine.com; A New Online Resource to Help ... 11 Oct 2005 ALTANA Inc Acquires US Dermatology Business from GlaxoSmithKline ... Sep 30, 2005 Connetics Reports Positive Results From Desilux Phase III Trial ... Aug 15, 2005 Connetics Names Luis Pena Vice President, Project Management ... Aug 22, 2005 Connetics Names Scott W. Meggs Senior Director, Corporate Counsel ... Aug 5, 2005 Connetics Receives FDA Non-Approvable Letter for Velac; Conference ... Jun 13, 2005 Connetics Files Resale Registration Statement Covering Its 2.00% ... Jun 20, 2005 Connetics Announces First Quarter Results with Product Sales up 79 ... Apr 26, 2005 Connetics Reports Highlights of 2005 Analyst and Investor Day ... Apr 14, 2005 Ventiv Announces New Partnership with Connetics Corporation Apr 14, 2005 Connetics Announces 2005 Analyst and Investor Day in New York City ... Mar 10, 2005 Barrier Therapeutics to Present Data on Azoline and Sebazole(TM) ... Feb 18, 2005 Other information Indication For the treatment of mild to moderate active Crohn's disease. Pharmacology Budesonide is a synthetic corticosteroid indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon. Budesonide is used in Crohn's disease to decrease the symptoms and inflammation associated with the disease, especially at times of flare up. Budesonide has a high topical glucocorticosteroid (GCS) activity and a substantial first pass elimination. The formulation contains granules which are coated to protect dissolution in gastric juice, but which dissolve at pH >5.5, ie, normally when the granules reach the duodenum. Thereafter, a matrix of ethylcellulose with budesonide controls the release of the drug into the intestinal lumen in a time-dependent manner. Mechanism Of Action The exact mechanism of action of budesonide in the treatment of Crohn's disease is not fully understood. However, being a glucocorticosteroid, budesonide has a high local anti-inflammatory effect. Drug Category Bronchodilator Agents; Anti-inflammatory Agents; Corticosteroids; ATC:A07EA06; ATC:D07AC09; ATC:R01AD05; ATC:R03BA02 Brand Names/Synonyms Bidien; Budeson; Budesonide; Budesonide, Pharma; BudesonideÊ; Cortivent; Desonide; Desowen; Entocort; Entocort Ec; Micronyl; Preferid; Pulmicort; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Turbuhaler; Rhinocort; Rhinocort Aqua; Rhinocort Turbuhaler; Spirocort; Tridesilon Dosage Forms CAPSULE (SUSTAINED-RELEASE); METERED-DOSE (AEROSOL); SUSPENSION Absorption Complete Interactions Interactions for Budesonide: Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered. After extensive intake of grapefruit juice (which inhibits CYP3A4 activity predominantly in the intestinal mucosa), the systemic exposure for oral budesonide increased about two times. As with other drugs primarily being metabolized through CYP3A4, ingestion of grapefruit or grapefruit juice should be avoided in connection with budesonide administration. Chemical IUPAC Name Not Available Chemical Formula C25H34O6 Half Life 2.0 and 3.6 hours Drug Type Approved Drug # Accession No APRD00442 CAS Registry Number 51333-22-3 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |